For women with ovarian cancer, the addition of bevacizumab to standard chemotherapy results in significantly improved progression-free survival (PFS).
Your search for bevacizumab returned 71 results
Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who have progressed after discontinuation of first-line bevacizumab and chemotherapy.
The systemic safety of bevacizumab appears to be similar to that of ranibizumab as intravitreal therapy for neovascular age-related macular degeneration (AMD).
The addition of bevacizumab to carboplatin and paclitaxel chemotherapy for the first-line treatment of women with ovarian cancer may offer benefit compared with standard chemotherapy alone, particularly for patients with more aggressive disease, investigators noted in a presentation during the American Society of Clinical Oncology’s 2011 Annual Meeting.
Adjuvant bevacizumab increases overall survival in cervical cancer and improves progression-free survival in glioblastoma.
At two years of follow-up, diabetes-related clinically significant macular edema (CSME) is more effectively improved by intravitreous bevacizumab than with macular laser therapy (MLT).
No evidence of infection, inflammation when bevacizumab is stored at 4 Celsius for a week
Persistent diabetic macular edema more likely with bevacizumab than aflibercept or ranibizumab
Both linked to improvements in visual acuity; only triamcinolone tied to sustained improvement in CMT
After completion of the initial bevacizumab treatment cycle, there was a significant reduction in epistaxis severity scores and RBC transfusion requirements.